iShares US Medical Devices ETF
489 hedge funds and large institutions have $4.31B invested in iShares US Medical Devices ETF in 2020 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 219 increasing their positions, 123 reducing their positions, and 47 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 219 | Existing positions reduced: 123
55% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 47
24% more capital invested
Capital invested by funds: $3.48B → $4.31B (+$836M)
13% more funds holding in top 10
Funds holding in top 10: 23 → 26 (+3)
4.83% more ownership
Funds ownership: 311.54% → 316.37% (+4.8%)
4% more funds holding
Funds holding: 468 → 489 (+21)
85% less call options, than puts
Call options by funds: $13.3M | Put options by funds: $85.7M
Top Buyers
Top Sellers
IHI Hedge Fund Activity: Q3 2020 in Review
489 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in iShares US Medical Devices ETF (IHI) for Q3 2020, worth a combined $4.31B — up 24% from $3.48B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new IHI positions and 47 closed out — a net gain of 26 holders — while 219 added to existing stakes and 123 trimmed.
The largest buyer was Churchill Management, adding an estimated $175M. The largest seller was Morgan Stanley, cutting an estimated $202M.
- 489 institutional investors held iShares US Medical Devices ETF (IHI) as of Q3 2020, up from 468 in Q2 2020.
- Funds reported $4.31B of iShares US Medical Devices ETF stock for Q3 2020, up 24% quarter-over-quarter.
- 73 funds opened new iShares US Medical Devices ETF positions in Q3 2020 and 47 closed out, a net change of +26 holders.
- The largest iShares US Medical Devices ETF buyer in Q3 2020 was Churchill Management, an estimated $175M added.
- The largest iShares US Medical Devices ETF seller in Q3 2020 was Morgan Stanley, an estimated $202M sold.
Based on aggregated 13F filings for Q3 2020.